炎症性肠病治疗药物的血栓栓塞风险和治疗现状

Thromboembolism Risk and Treatment of Therapeutic Agents for Inflammatory Bowel Disease

炎症性肠病(IBD)是一种慢性复发性肠道和全身性炎性疾病,IBD患者发生静脉血栓栓塞和急性动脉事件的风险增加。美国食品和药品管理局(FDA)多次报告了Janus激酶(JAK)抑制剂与血栓栓塞不良事件,表明药物治疗在促进或抗血栓平衡的调节中起着相关作用。本文就IBD治疗药物的血栓栓塞风险和治疗现状作一综述,旨在总结每种单一药物治疗对IBD患者动静脉血栓栓塞风险的影响,以及静脉血栓栓塞预防的安全性和有效性,以期减少IBD患者的血栓栓塞事件,实现IBD个性化治疗。

Inflammatory bowel disease(IBD)is a chronic recurrent intestinal disease as well as systemic inflammatory disease,and patients with IBD have an increased risk of venous thromboembolism and acute arterial events.Multiple reports on Janus kinases(JAK)inhibitors and thromboembolic adverse events have been reported by the Food and Drug Administration(FDA),which indicates that drug therapy also plays a relevant role in promoting or regulating antithrombotic balance.This article reviewed the thromboembolism risk and the treatment of therapeutic agents for IBD,aiming to summarize the effect of each monotherapy on the risk of arterial and venous thromboembolism in patients with IBD,and assess the safety and effectiveness of venous thromboembolism prophylaxis,so as to reduce the incidence rate of thromboembolism events and personalize treatment of IBD.